Sunday, December 07, 2025 | 01:54 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Cipla to collaborate with US-based MEDRx for muscle relaxant drug

As per the deal, MEDRx to receive upfront payment of about $ 30 mn & will be eligible for royalties

Cipla to collaborate with US-based MEDRx for muscle relaxant drug
premium

BS B2B Bureau Mumbai
Cipla USA Inc, the wholly-owned subsidiary of the Mumbai-based pharmaceutical company Cipla, has signed a worldwide licensing agreement (except for East Asia) with MEDRx Company Limited (MEDRx) to further develop and commercialise MRX-4TZT, a tizanidine patch for the management of Spasticity. Tizanidine is a type of central analgesic (acts on the central nerves in the brain and the spinal cord to relieve muscle tonicity). This drug is used to alleviate discomfort from shoulder stiffness, back problems, frozen shoulder, tension headaches and other problems.

Under the terms of the agreement, MEDRx is eligible to receive up to $ 30 million cumulatively through